{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:39:11Z","timestamp":1793612351812,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Anaplastic thyroid cancer (ATC) is an aggressive and rare disease. Rapid metastasis and limited treatments call for additional therapeutic options, including drug repurposing. The early spreading of ATC highlights the importance of rapid therapy success assessment, which could be achieved by measurement of extracellular vesicle (EV)-associated cell-free RNA in liquid biopsy samples. Recent studies have discovered the potential of the receptor tyrosine kinase inhibitor vandetanib for ATC treatment in vitro and in vivo. Given the rarity of ATC patients receiving off-label vandetanib treatment, acquiring patient samples for clinical studies is a prolonged process, and pre-clinical investigations are needed to elucidate the effects of vandetanib on ATC cells. Here, we present an in vitro study addressing holistic transcriptional and proteomic changes induced in the ATC cell line Cal62 by three doses of vandetanib and quantified by high-throughput methods. By comparing the transcriptional and proteomic data sets and applying dimensional reduction models such as sparse partial least-squares discriminant analysis, we refined a set of 21 biomarker candidates. Out of these, we report a final signature of eight transcriptional biomarkers, validated in cellular and cell-free RNA by RT-qPCR and verified for biological significance and discriminatory power by pathway over-representation analysis and partial least-squares regression. This transcriptional biomarker signature can distinguish vandetanib treatment from control in cell-free RNA isolated from Cal62 EVs and can be measured reliably, easily, and quickly using RT-qPCR. Our findings may serve as a basis for future clinical trials with liquid biopsy samples from ATC patients undergoing off-label vandetanib treatment.<\/jats:p>","DOI":"10.1038\/s41598-025-18319-w","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T09:19:59Z","timestamp":1757668799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9356-7940","authenticated-orcid":false,"given":"Christian","family":"Gr\u00e4tz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5892-8706","authenticated-orcid":false,"given":"Prashant","family":"Changoer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapi Menglin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3882-0093","authenticated-orcid":false,"given":"Johannes","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-493X","authenticated-orcid":false,"given":"Martin","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-0460","authenticated-orcid":false,"given":"Romana","family":"Netea-Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6333-5233","authenticated-orcid":false,"given":"Susanne I.","family":"Wudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6131-7322","authenticated-orcid":false,"given":"Christina","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-4168","authenticated-orcid":false,"given":"Markus","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-0148","authenticated-orcid":false,"given":"Benedikt","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9113-9643","authenticated-orcid":false,"given":"Marlene","family":"Reithmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-1019","authenticated-orcid":false,"given":"Michael W.","family":"Pfaffl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"18319_CR1","unstructured":"American Cancer Society (Atlanta: American Cancer Society; 2024)."},{"key":"18319_CR2","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas, M. E., McFadden, D. G. & Durante, C. Thyroid cancer. Lancet 388, 2783\u20132795. https:\/\/doi.org\/10.1016\/S0140-6736(16)30172-6 (2016).","journal-title":"Lancet"},{"key":"18319_CR3","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.beem.2022.101678","volume":"37","author":"SN Rao","year":"2023","unstructured":"Rao, S. N. & Smallridge, R. C. Anaplastic thyroid cancer: An update. Best Pract. Res. Clin. Endocrinol. Metab 37, 101678. https:\/\/doi.org\/10.1016\/j.beem.2022.101678 (2023).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab"},{"key":"18319_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible, K. C. et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31, 337\u2013386. https:\/\/doi.org\/10.1089\/thy.2020.0944 (2021).","journal-title":"Thyroid"},{"key":"18319_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00423-006-0104-y","volume":"391","author":"S Hoffmann","year":"2006","unstructured":"Hoffmann, S. et al. Targeting the EGF\/VEGF-R system by tyrosine-kinase inhibitors\u2014a novel antiproliferative\/antiangiogenic strategy in thyroid cancer. Langenbecks Arch. Surg. 391, 589\u2013596. https:\/\/doi.org\/10.1007\/s00423-006-0104-y (2006).","journal-title":"Langenbecks Arch. Surg."},{"key":"18319_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2174\/138920211798120808","volume":"12","author":"A Antonelli","year":"2011","unstructured":"Antonelli, A. et al. New targeted therapies for thyroid cancer. Curr. Genomics 12, 626\u2013631. https:\/\/doi.org\/10.2174\/138920211798120808 (2011).","journal-title":"Curr. Genomics"},{"key":"18319_CR7","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"Smallridge, R. C. et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22, 1104\u20131139. https:\/\/doi.org\/10.1089\/thy.2012.0302 (2012).","journal-title":"Thyroid"},{"key":"18319_CR8","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1158\/1078-0432.ccr-16-0484","volume":"22","author":"F Raue","year":"2016","unstructured":"Raue, F. & Frank-Raue, K. Thyroid cancer: Risk-stratified management and individualized therapy. Clin. Cancer Res. 22, 5012\u20135021. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0484 (2016).","journal-title":"Clin. Cancer Res."},{"key":"18319_CR9","unstructured":"European Medicines Agency (EMA) Caprelsa Produktinformationen. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/caprelsa (2024)."},{"key":"18319_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33, 406\u2013415. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014 (2022).","journal-title":"Ann. Oncol."},{"key":"18319_CR11","doi-asserted-by":"publisher","first-page":"e220179","DOI":"10.1530\/ETJ-22-0179","volume":"12","author":"I Dam\u00e1sio","year":"2023","unstructured":"Dam\u00e1sio, I. et al. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. Eur. Thyroid J. 12, e220179. https:\/\/doi.org\/10.1530\/ETJ-22-0179 (2023).","journal-title":"Eur. Thyroid J."},{"key":"18319_CR12","doi-asserted-by":"publisher","first-page":"e220062","DOI":"10.1530\/EO-22-0062","volume":"3","author":"V Sukrithan","year":"2023","unstructured":"Sukrithan, V., Jain, P., Shah, M. H. & Konda, B. Kinase inhibitors in thyroid cancers. Endocrine Oncol. 3, e220062. https:\/\/doi.org\/10.1530\/EO-22-0062 (2023).","journal-title":"Endocrine Oncol."},{"key":"18319_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2020.01.005","volume":"61","author":"N Pozdeyev","year":"2020","unstructured":"Pozdeyev, N., Rose, M. M., Bowles, D. W. & Schweppe, R. E. Molecular therapeutics for anaplastic thyroid cancer. Semin. Cancer Biol. 61, 23\u201329. https:\/\/doi.org\/10.1016\/j.semcancer.2020.01.005 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"18319_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1530\/erc-19-0011","volume":"26","author":"K Wong","year":"2019","unstructured":"Wong, K., Di Cristofano, F., Ranieri, M., De Martino, D. & Di Cristofano, A. PI3K\/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer. Endocr. Relat. Cancer 26, 425\u2013436. https:\/\/doi.org\/10.1530\/erc-19-0011 (2019).","journal-title":"Endocr. Relat. Cancer"},{"key":"18319_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7869","author":"Z Li","year":"2019","unstructured":"Li, Z., Zhang, Y., Wang, R., Zou, K. & Zou, L. Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (review). Exp. Therapeut. Med. https:\/\/doi.org\/10.3892\/etm.2019.7869 (2019).","journal-title":"Exp. Therapeut. Med."},{"key":"18319_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks, C. et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31, 1076\u20131085. https:\/\/doi.org\/10.1089\/thy.2020.0322 (2021).","journal-title":"Thyroid"},{"key":"18319_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/cancers14041061","volume":"14","author":"A Jannin","year":"2022","unstructured":"Jannin, A. et al. Anaplastic thyroid carcinoma: An update. Cancers 14, 1061. https:\/\/doi.org\/10.3390\/cancers14041061 (2022).","journal-title":"Cancers"},{"key":"18319_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05709-z","author":"Z Jingtai","year":"2023","unstructured":"Jingtai, Z. et al. Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-023-05709-z (2023).","journal-title":"Cell Death Dis."},{"key":"18319_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1530\/erc-14-0299","volume":"21","author":"E Baldini","year":"2014","unstructured":"Baldini, E. et al. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. Endocrine Relat. Cancer 21, 797\u2013811. https:\/\/doi.org\/10.1530\/erc-14-0299 (2014).","journal-title":"Endocrine Relat. Cancer"},{"key":"18319_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02076-x","author":"J Li","year":"2024","unstructured":"Li, J. et al. Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study. Mol. Cancer https:\/\/doi.org\/10.1186\/s12943-024-02076-x (2024).","journal-title":"Mol. Cancer"},{"key":"18319_CR21","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas, M. E., Ryder, M. & Jimenez, C. Targeted therapy for advanced thyroid cancer: Kinase inhibitors and beyond. Endocr. Rev. 40, 1573\u20131604. https:\/\/doi.org\/10.1210\/er.2019-00007 (2019).","journal-title":"Endocr. Rev."},{"key":"18319_CR22","doi-asserted-by":"publisher","first-page":"8594","DOI":"10.1158\/1078-0432.ccr-04-0690","volume":"10","author":"BA Schiff","year":"2004","unstructured":"Schiff, B. A. et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin. Cancer Res. 10, 8594\u20138602. https:\/\/doi.org\/10.1158\/1078-0432.ccr-04-0690 (2004).","journal-title":"Clin. Cancer Res."},{"key":"18319_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1196\/annals.1329.009","volume":"1030","author":"C Ensinger","year":"2004","unstructured":"Ensinger, C. et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. N. Y. Acad. Sci. 1030, 69\u201377. https:\/\/doi.org\/10.1196\/annals.1329.009 (2004).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"18319_CR24","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6305","author":"S Ferrari","year":"2018","unstructured":"Ferrari, S. et al. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. Oncol. Rep. https:\/\/doi.org\/10.3892\/or.2018.6305 (2018).","journal-title":"Oncol. Rep."},{"key":"18319_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00764","author":"SM Ferrari","year":"2018","unstructured":"Ferrari, S. M. et al. Antineoplastic effect of lenvatinib and vandetanib in primary anaplastic thyroid cancer cells obtained from biopsy or fine needle aspiration. Front. Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2018.00764 (2018).","journal-title":"Front. Endocrinol."},{"key":"18319_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000486422","volume":"85","author":"E Chmielik","year":"2018","unstructured":"Chmielik, E. et al. Heterogeneity of thyroid cancer. Pathobiology 85, 117\u2013129. https:\/\/doi.org\/10.1159\/000486422 (2018).","journal-title":"Pathobiology"},{"key":"18319_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1159\/000478018","volume":"40","author":"S Mader","year":"2017","unstructured":"Mader, S. & Pantel, K. Liquid biopsy: Current status and future perspectives. Oncol. Res. Treat. 40, 404\u2013408. https:\/\/doi.org\/10.1159\/000478018 (2017).","journal-title":"Oncol. Res. Treat."},{"key":"18319_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel, G., D\u2019Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213\u2013228. https:\/\/doi.org\/10.1038\/nrm.2017.125 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"18319_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrc3066","volume":"11","author":"H Schwarzenbach","year":"2011","unstructured":"Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426\u2013437. https:\/\/doi.org\/10.1038\/nrc3066 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"18319_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12140","author":"E\u00c1 T\u00f3th","year":"2021","unstructured":"T\u00f3th, E. \u00c1. et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J. Extracell. Vesicles https:\/\/doi.org\/10.1002\/jev2.12140 (2021).","journal-title":"J. Extracell. Vesicles"},{"key":"18319_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41698-022-00270-y","volume":"6","author":"B Roskams-Hieter","year":"2022","unstructured":"Roskams-Hieter, B. et al. Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies. NPJ Precis. Oncol. 6, 28. https:\/\/doi.org\/10.1038\/s41698-022-00270-y (2022).","journal-title":"NPJ Precis. Oncol."},{"key":"18319_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040458","author":"L Sorber","year":"2019","unstructured":"Sorber, L. et al. Circulating cell-free DNA and RNA analysis as liquid biopsy: Optimal centrifugation protocol. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11040458 (2019).","journal-title":"Cancers (Basel)"},{"key":"18319_CR33","doi-asserted-by":"publisher","first-page":"e16261","DOI":"10.1016\/j.heliyon.2023.e16261","volume":"9","author":"M Albitar","year":"2023","unstructured":"Albitar, M. et al. Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors. Heliyon 9, e16261. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16261 (2023).","journal-title":"Heliyon"},{"key":"18319_CR34","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/s41467-021-22444-1","volume":"12","author":"MH Larson","year":"2021","unstructured":"Larson, M. H. et al. A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection. Nat. Commun. 12, 2357. https:\/\/doi.org\/10.1038\/s41467-021-22444-1 (2021).","journal-title":"Nat. Commun."},{"key":"18319_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic\u2014implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297\u2013312. https:\/\/doi.org\/10.1038\/s41571-020-00457-x (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"18319_CR36","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/0008-5472.CAN-13-2030","volume":"73","author":"K Pantel","year":"2013","unstructured":"Pantel, K. & Alix-Panabieres, C. Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 73, 6384\u20136388. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2030 (2013).","journal-title":"Cancer Res."},{"key":"18319_CR37","doi-asserted-by":"publisher","first-page":"869108","DOI":"10.3389\/fonc.2022.869108","volume":"12","author":"A Tosevska","year":"2022","unstructured":"Tosevska, A. et al. Cell-free RNA as a novel biomarker for response to therapy in head & neck cancer. Front. Oncol. 12, 869108. https:\/\/doi.org\/10.3389\/fonc.2022.869108 (2022).","journal-title":"Front. Oncol."},{"key":"18319_CR38","unstructured":"Gr\u00e4tz, C. Figure 1: Overview of the study design, goals, and experiments. Created with BioRender.com. Created in BioRender: https:\/\/BioRender.com\/1gfu3mq (2025)."},{"key":"18319_CR39","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-10-2762","volume":"17","author":"MK Gule","year":"2011","unstructured":"Gule, M. K. et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin. Cancer Res. 17, 2281\u20132291. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2762 (2011).","journal-title":"Clin. Cancer Res."},{"key":"18319_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1634\/theoncologist.2010-0317","volume":"16","author":"C Nucera","year":"2011","unstructured":"Nucera, C. et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16, 296\u2013309. https:\/\/doi.org\/10.1634\/theoncologist.2010-0317 (2011).","journal-title":"Oncologist"},{"key":"18319_CR41","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437-1452.e1417. https:\/\/doi.org\/10.1016\/j.cell.2017.10.049 (2017).","journal-title":"Cell"},{"key":"18319_CR42","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"key":"18319_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"18319_CR44","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"18319_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41580-023-00576-0","volume":"24","author":"AC Dixson","year":"2023","unstructured":"Dixson, A. C., Dawson, T. R., Di Vizio, D. & Weaver, A. M. Context-specific regulation of extracellular vesicle biogenesis and cargo selection. Nat. Rev. Mol. Cell Biol. 24, 454\u2013476. https:\/\/doi.org\/10.1038\/s41580-023-00576-0 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"18319_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-022-01277-4","author":"T O\u2019Grady","year":"2022","unstructured":"O\u2019Grady, T. et al. Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels. BMC Biol. https:\/\/doi.org\/10.1186\/s12915-022-01277-4 (2022).","journal-title":"BMC Biol."},{"key":"18319_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2967\/jnumed.110.081745","volume":"52","author":"MA Walter","year":"2011","unstructured":"Walter, M. A. et al. Metabolic imaging allows early prediction of response to vandetanib. J. Nucl. Med. 52, 231\u2013240. https:\/\/doi.org\/10.2967\/jnumed.110.081745 (2011).","journal-title":"J. Nucl. Med."},{"key":"18319_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/erc-09-0292","volume":"18","author":"D Vitagliano","year":"2010","unstructured":"Vitagliano, D. et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine Relat. Cancer 18, 1\u201311. https:\/\/doi.org\/10.1677\/erc-09-0292 (2010).","journal-title":"Endocrine Relat. Cancer"},{"key":"18319_CR49","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s11095-022-03420-w","volume":"40","author":"N Erwin","year":"2023","unstructured":"Erwin, N., Serafim, M. F. & He, M. Enhancing the cellular production of extracellular vesicles for developing therapeutic applications. Pharm. Res. 40, 833\u2013853. https:\/\/doi.org\/10.1007\/s11095-022-03420-w (2023).","journal-title":"Pharm. Res."},{"key":"18319_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12404","author":"JA Welsh","year":"2024","unstructured":"Welsh, J. A. et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J. Extracell. Vesicles https:\/\/doi.org\/10.1002\/jev2.12404 (2024).","journal-title":"J. Extracell. Vesicles"},{"key":"18319_CR51","doi-asserted-by":"publisher","first-page":"1481321","DOI":"10.1080\/20013078.2018.1481321","volume":"7","author":"D Buschmann","year":"2018","unstructured":"Buschmann, D. et al. Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by next-generation sequencing. J. Extracell. Vesicles 7, 1481321. https:\/\/doi.org\/10.1080\/20013078.2018.1481321 (2018).","journal-title":"J. Extracell. Vesicles"},{"key":"18319_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/cpcb.110","author":"C Coughlan","year":"2020","unstructured":"Coughlan, C. et al. Exosome isolation by ultracentrifugation and precipitation and techniques for downstream analyses. Curr. Protocols Cell Biol. https:\/\/doi.org\/10.1002\/cpcb.110 (2020).","journal-title":"Curr. Protocols Cell Biol."},{"key":"18319_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jim.2015.12.011","volume":"429","author":"RE Crossland","year":"2016","unstructured":"Crossland, R. E., Norden, J., Bibby, L. A., Davis, J. & Dickinson, A. M. Evaluation of optimal extracellular vesicle small RNA isolation and qRT-PCR normalisation for serum and urine. J. Immunol. Methods 429, 39\u201349. https:\/\/doi.org\/10.1016\/j.jim.2015.12.011 (2016).","journal-title":"J. Immunol. Methods"},{"key":"18319_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82488-3","author":"J Boulestreau","year":"2024","unstructured":"Boulestreau, J. et al. Salivary extracellular vesicles isolation methods impact the robustness of downstream biomarkers detection. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-024-82488-3 (2024).","journal-title":"Sci. Rep."},{"key":"18319_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-022-00409-w","volume":"10","author":"L Cab\u00fas","year":"2022","unstructured":"Cab\u00fas, L., Lagarde, J., Curado, J., Lizano, E. & Perez-Boza, J. Current challenges and best practices for cell-free long RNA biomarker discovery. Biomark Res 10, 62. https:\/\/doi.org\/10.1186\/s40364-022-00409-w (2022).","journal-title":"Biomark Res"},{"key":"18319_CR56","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/life12030386","volume":"12","author":"C Gr\u00e4tz","year":"2022","unstructured":"Gr\u00e4tz, C. et al. Obtaining reliable RT-qPCR results in molecular diagnostics-MIQE goals and pitfalls for transcriptional biomarker discovery. Life 12, 386. https:\/\/doi.org\/10.3390\/life12030386 (2022).","journal-title":"Life"},{"key":"18319_CR57","doi-asserted-by":"publisher","first-page":"101269","DOI":"10.1016\/j.mam.2024.101269","volume":"97","author":"C Gr\u00e4tz","year":"2024","unstructured":"Gr\u00e4tz, C. et al. A pipeline for the development and analysis of extracellular vesicle-based transcriptomic biomarkers in molecular diagnostics. Mol. Aspects Med. 97, 101269. https:\/\/doi.org\/10.1016\/j.mam.2024.101269 (2024).","journal-title":"Mol. Aspects Med."},{"key":"18319_CR58","doi-asserted-by":"publisher","first-page":"e844","DOI":"10.1371\/journal.pone.0000844","volume":"2","author":"SK Kachhap","year":"2007","unstructured":"Kachhap, S. K. et al. The N-Myc down regulated gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS ONE 2, e844. https:\/\/doi.org\/10.1371\/journal.pone.0000844 (2007).","journal-title":"PLoS ONE"},{"key":"18319_CR59","doi-asserted-by":"publisher","first-page":"a011254","DOI":"10.1101\/cshperspect.a011254","volume":"4","author":"DK Morrison","year":"2012","unstructured":"Morrison, D. K. MAP kinase pathways. Cold Spring Harb. Perspect. Biol. 4, a011254\u2013a011254. https:\/\/doi.org\/10.1101\/cshperspect.a011254 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"18319_CR60","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/s0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 Is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735\u2013745. https:\/\/doi.org\/10.1016\/s0092-8674(00)81402-6 (1998).","journal-title":"Cell"},{"key":"18319_CR61","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.86183","author":"H Jin","year":"2019","unstructured":"Jin, H., Zhang, L., Wang, S. & Qian, L. BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway. Arch. Med. Sci. https:\/\/doi.org\/10.5114\/aoms.2019.86183 (2019).","journal-title":"Arch. Med. Sci."},{"key":"18319_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1042\/bj3220403","volume":"322","author":"S Brunner","year":"1997","unstructured":"Brunner, S., Kramar, K., Denhardt, D. T. & Hofbauer, R. Cloning and characterization of murine carnitine acetyltransferase: evidence for a requirement during cell cycle progression. Biochem. J. 322, 403\u2013410. https:\/\/doi.org\/10.1042\/bj3220403 (1997).","journal-title":"Biochem. J."},{"key":"18319_CR63","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Thery","year":"2018","unstructured":"Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J. Extracell Vesicles 7, 1535750. https:\/\/doi.org\/10.1080\/20013078.2018.1535750 (2018).","journal-title":"J. Extracell Vesicles"},{"key":"18319_CR64","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1006\/bbrc.1999.0678","volume":"258","author":"Y Wen","year":"1999","unstructured":"Wen, Y., Edelman, J. L., Kang, T. & Sachs, G. Lipocortin V may function as a signaling protein for vascular endothelial growth factor receptor-2\/Flk-1. Biochem. Biophys. Res. Commun. 258, 713\u2013721. https:\/\/doi.org\/10.1006\/bbrc.1999.0678 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"18319_CR65","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/19336918.2016.1264559","volume":"11","author":"N Heitzig","year":"2017","unstructured":"Heitzig, N. et al. Annexin A8 promotes VEGF-A driven endothelial cell sprouting. Cell Adh. Migr. 11, 275\u2013287. https:\/\/doi.org\/10.1080\/19336918.2016.1264559 (2017).","journal-title":"Cell Adh. Migr."},{"key":"18319_CR66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1196\/annals.1339.047","volume":"1059","author":"D Yu","year":"2005","unstructured":"Yu, D., Cozma, D., Park, A. & Thomas-Tikhonenko, A. Functional validation of genes implicated in lymphomagenesis: An in vivo selection assay using a Myc-induced B-Cell tumor. Ann. N. Y. Acad. Sci. 1059, 145\u2013159. https:\/\/doi.org\/10.1196\/annals.1339.047 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"18319_CR67","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/gb-2003-4-10-r69","volume":"4","author":"KI Zeller","year":"2003","unstructured":"Zeller, K. I., Jegga, A. G., Aronow, B. J., O\u2019Donnell, K. A. & Dang, C. V. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 4, R69. https:\/\/doi.org\/10.1186\/gb-2003-4-10-r69 (2003).","journal-title":"Genome Biol."},{"key":"18319_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/jco.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells, S. A. Jr. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134\u2013141. https:\/\/doi.org\/10.1200\/jco.2011.35.5040 (2012).","journal-title":"J. Clin. Oncol."},{"key":"18319_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bbcan.2018.11.006","volume":"1871","author":"KB Johnsen","year":"2019","unstructured":"Johnsen, K. B., Gudbergsson, J. M., Andresen, T. L. & Simonsen, J. B. What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer. Biochim. Biophys. Acta (BBA) Rev. Cancer 1871, 109\u2013116. https:\/\/doi.org\/10.1016\/j.bbcan.2018.11.006 (2019).","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"18319_CR70","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/cells8121637","volume":"8","author":"J Lobo","year":"2019","unstructured":"Lobo, J. et al. Identification and validation model for informative liquid biopsy-based microRNA biomarkers: Insights from germ cell tumor in vitro in vivo patient-derived data. Cells 8, 1637. https:\/\/doi.org\/10.3390\/cells8121637 (2019).","journal-title":"Cells"},{"key":"18319_CR71","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/cts.13372","volume":"15","author":"S Derderian","year":"2022","unstructured":"Derderian, S. et al. Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. Clin. Transl. Sci. 15, 2597\u20132612. https:\/\/doi.org\/10.1111\/cts.13372 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"18319_CR72","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.1158\/1078-0432.ccr-14-0361","volume":"20","author":"T Katsila","year":"2014","unstructured":"Katsila, T. et al. Circulating pEGFR Is a candidate response biomarker of Cetuximab therapy in colorectal cancer. Clin. Cancer Res. 20, 6346\u20136356. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0361 (2014).","journal-title":"Clin. Cancer Res."},{"key":"18319_CR73","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2147\/ott.s475644","volume":"17","author":"J Simiene","year":"2024","unstructured":"Simiene, J. et al. Prognostic value of miR-10a-3p in non-small cell lung cancer patients. OncoTarg. Ther. 17, 1017\u20131032. https:\/\/doi.org\/10.2147\/ott.s475644 (2024).","journal-title":"OncoTarg. Ther."},{"key":"18319_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/0471143030.cb0322s30","author":"C Thery","year":"2006","unstructured":"Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. https:\/\/doi.org\/10.1002\/0471143030.cb0322s30 (2006).","journal-title":"Curr. Protoc. Cell Biol."},{"key":"18319_CR75","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nprot.2010.43","volume":"5","author":"L Young","year":"2010","unstructured":"Young, L., Sung, J., Stacey, G. & Masters, J. R. Detection of Mycoplasma in cell cultures. Nat. Protoc. 5, 929\u2013934. https:\/\/doi.org\/10.1038\/nprot.2010.43 (2010).","journal-title":"Nat. Protoc."},{"key":"18319_CR76","doi-asserted-by":"publisher","first-page":"26913","DOI":"10.3402\/jev.v3.26913","volume":"3","author":"J L\u00f6tvall","year":"2014","unstructured":"L\u00f6tvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the international society for extracellular vesicles. J. Extracell. Vesicles 3, 26913. https:\/\/doi.org\/10.3402\/jev.v3.26913 (2014).","journal-title":"J. Extracell. Vesicles"},{"key":"18319_CR77","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278. https:\/\/doi.org\/10.1038\/s41587-020-0439-x (2020).","journal-title":"Nat. Biotechnol."},{"key":"18319_CR78","doi-asserted-by":"publisher","unstructured":"Patel, H. et al. nf-core\/rnaseq: nf-core\/rnaseq, v3.18.0 - Lithium Lynx. https:\/\/doi.org\/10.5281\/zenodo.1400710 (2024).","DOI":"10.5281\/zenodo.1400710"},{"key":"18319_CR79","unstructured":"R Core Team R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 4.4.1 https:\/\/www.R-project.org\/ (2024)."},{"key":"18319_CR80","unstructured":"Posit Team RStudio: Integrated Development Environment for R, Posit Software, PBC, Boston, MA, 2024.9.1.394 http:\/\/www.posit.co\/ (2024)."},{"key":"18319_CR81","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/bioinformatics\/bts611","volume":"28","author":"E Kopylova","year":"2012","unstructured":"Kopylova, E., No\u00e9, L. & Touzet, H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics 28, 3211\u20133217. https:\/\/doi.org\/10.1093\/bioinformatics\/bts611 (2012).","journal-title":"Bioinformatics"},{"key":"18319_CR82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635 (2013).","journal-title":"Bioinformatics"},{"key":"18319_CR83","doi-asserted-by":"publisher","first-page":"D948","DOI":"10.1093\/nar\/gkae1071","volume":"53","author":"SC Dyer","year":"2025","unstructured":"Dyer, S. C. et al. Ensembl 2025. Nucleic Acids Res. 53, D948\u2013D957. https:\/\/doi.org\/10.1093\/nar\/gkae1071 (2025).","journal-title":"Nucleic Acids Res."},{"key":"18319_CR84","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419. https:\/\/doi.org\/10.1038\/nmeth.4197 (2017).","journal-title":"Nat. Methods"},{"key":"18319_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"18319_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005752","author":"F Rohart","year":"2017","unstructured":"Rohart, F. et al. mixOmics: An R package for omics feature selection and multiple data integration. PLoS Comput. Biol. https:\/\/doi.org\/10.1371\/journal.pcbi.1005752 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"18319_CR87","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 19, 3292\u20133320. https:\/\/doi.org\/10.1038\/s41596-024-01020-z (2024).","journal-title":"Nat. Protoc."},{"key":"18319_CR88","unstructured":"Dolgalev, I. msigdbr: MSigDB gene sets for multiple organisms in a tidy data format. https:\/\/igordot.github.io\/msigdbr\/ (2025)."},{"key":"18319_CR89","doi-asserted-by":"publisher","first-page":"1388769","DOI":"10.3389\/fimmu.2024.1388769","volume":"15","author":"M Schuster","year":"2024","unstructured":"Schuster, M. et al. Extracellular vesicles secreted by 3D tumor organoids are enriched for immune regulatory signaling biomolecules compared to conventional 2D glioblastoma cell systems. Front. Immunol. 15, 1388769. https:\/\/doi.org\/10.3389\/fimmu.2024.1388769 (2024).","journal-title":"Front. Immunol."},{"key":"18319_CR90","doi-asserted-by":"publisher","first-page":"100917","DOI":"10.1016\/j.mcpro.2025.100917","volume":"24","author":"M Abele","year":"2025","unstructured":"Abele, M. et al. Proteomic diversity in bacteria: insights and implications for bacterial identification. Mol. Cell. Proteom. 24, 100917. https:\/\/doi.org\/10.1016\/j.mcpro.2025.100917 (2025).","journal-title":"Mol. Cell. Proteom."},{"key":"18319_CR91","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/nprot.2016.136","volume":"11","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 11, 2301\u20132319. https:\/\/doi.org\/10.1038\/nprot.2016.136 (2016).","journal-title":"Nat. Protoc."},{"key":"18319_CR92","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1021\/pr101065j","volume":"10","author":"J Cox","year":"2011","unstructured":"Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794\u20131805. https:\/\/doi.org\/10.1021\/pr101065j (2011).","journal-title":"J. Proteome Res."},{"key":"18319_CR93","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740. https:\/\/doi.org\/10.1038\/nmeth.3901 (2016).","journal-title":"Nat. Methods"},{"key":"18319_CR94","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin, S. A. et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611\u2013622. https:\/\/doi.org\/10.1373\/clinchem.2008.112797 (2009).","journal-title":"Clin. Chem."},{"key":"18319_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaf043","author":"SA Bustin","year":"2025","unstructured":"Bustin, S. A. et al. MIQE 2.0: Revision of the minimum information for publication of quantitative real-time PCR experiments guidelines. Clin. Chem. https:\/\/doi.org\/10.1093\/clinchem\/hvaf043 (2025).","journal-title":"Clin. Chem."},{"key":"18319_CR96","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/bioinformatics\/btm091","volume":"23","author":"T Koressaar","year":"2007","unstructured":"Koressaar, T. & Remm, M. Enhancements and modifications of primer design program Primer3. Bioinformatics 23, 1289\u20131291. https:\/\/doi.org\/10.1093\/bioinformatics\/btm091 (2007).","journal-title":"Bioinformatics"},{"key":"18319_CR97","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/bioinformatics\/bty036","volume":"34","author":"T Koressaar","year":"2018","unstructured":"Koressaar, T. et al. Primer3_masker: integrating masking of template sequence with primer design software. Bioinformatics 34, 1937\u20131938. https:\/\/doi.org\/10.1093\/bioinformatics\/bty036 (2018).","journal-title":"Bioinformatics"},{"key":"18319_CR98","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/nar\/gks596","volume":"40","author":"A Untergasser","year":"2012","unstructured":"Untergasser, A. et al. Primer3\u2013new capabilities and interfaces. Nucleic Acids Res. 40, e115. https:\/\/doi.org\/10.1093\/nar\/gks596 (2012).","journal-title":"Nucleic Acids Res."},{"key":"18319_CR99","doi-asserted-by":"publisher","first-page":"research0034.00","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, research0034.0031. https:\/\/doi.org\/10.1186\/gb-2002-3-7-research0034 (2002).","journal-title":"Genome Biol."},{"key":"18319_CR100","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.can-04-0496","volume":"64","author":"CL Andersen","year":"2004","unstructured":"Andersen, C. L., Jensen, J. L. & \u00d8rntoft, T. F. Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Can. Res. 64, 5245\u20135250. https:\/\/doi.org\/10.1158\/0008-5472.can-04-0496 (2004).","journal-title":"Can. Res."},{"key":"18319_CR101","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45. https:\/\/doi.org\/10.1093\/nar\/29.9.e45 (2001).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18319-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:03:21Z","timestamp":1758056601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18319-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18319"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18319-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32464"}}